Premium
Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines
Author(s) -
Andersson Nadine G.,
Labarque Veerle,
Letelier Anna,
Mancuso Maria Elisa,
Bührlen Martina,
Fischer Kathelijn,
KartalKaess Mutlu,
Koskenvuo Minna,
Mikkelsen Torben,
Ljung Rolf
Publication year - 2020
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.24117
Subject(s) - medical genetics , biology , gene , phenotype , genetics , human genome , population , disease , nomenclature , genomics , prenatal diagnosis , genome , computational biology , medicine , taxonomy (biology) , pregnancy , fetus , botany , environmental health
Abstract In hemophilia A and B, analysis of the F8 and F9 gene variants enables carrier and prenatal diagnosis and prediction of risk for the development of inhibitors. The PedNet Registry collects clinical, genetic, and phenotypic data prospectively on more than 2000 children with hemophilia. The genetic reports of F8/F9 gene variants were classified uniformly to Human Genome Variation Society nomenclature and reevaluated using international population‐ and disease‐specific databases, literature survey and, where applicable, computational predictive programs. We report 88 novel variants in the F8 and F9 genes, 80 fulfilling criteria for Class 5 (pathogenic), six for Class 4 (likely pathogenic) and two fulfilling criteria for Class 3 (variant of unknown significance) of the American College of Medical Genetics and Genomics/Association for Molecular Pathologyguidelines together with information on the respective phenotype and inhibitor formation. The study highlights the need to reevaluate and update earlier genetic reports in hemophilia both locally but also in variant databases in light of changed nomenclature and new guidelines.